Find Bosutinib Monohydrate manufacturers, exporters & distributors on PharmaCompass

Bosutinib Monohydrate

Bosutinib Monohydrate

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

1 API Suppliers, 1 USDMF, 1 KDMF, 1 NDC API

PRICE INFORMATION

API Reference Price, API Exports, API Imports

DOSSIERs // Finished Dosage Formulations

9 Dossiers, 5 FDA Orange Book, 2 Europe, 2 Canada

DRUG PRODUCT COMPOSITION

TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 400MG BASE, TABLET;ORAL - EQ 500MG BASE, CAPSULE;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 50MG BASE

TABLET;ORAL - EQ 100MG BASE
TABLET;ORAL - EQ 400MG BASE
TABLET;ORAL - EQ 500MG BASE
CAPSULE;ORAL - EQ 100MG BASE
CAPSULE;ORAL - EQ 50MG BASE

RELATED EXCIPIENT COMPANIES

Suppliers, 10 Roquette, 10 Sigachi Industries, 7 Microlex e.U, 6 Gangwal Healthcare, 6 Kerry, 6 Gangwal Chemicals, 5 Corel Pharma Chem, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Prachin Chemical, 3 DFE Pharma, 3 Ideal Cures Pvt Ltd, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 3 Vasa Pharmachem, 2 Nanjing Well Pharmaceutical, 2 BASF, 1 Ingredion Pharma Solutions, 1 SPI Pharma, 1 Pharmatrans-Sanaq, 1 DKSH, 1 Jai Radhe Sales, 1 Nanjing Bold Chemical, 1 Aeon Procare

EXCIPIENTS BY APPLICATIONS

23 Fillers, Diluents & Binders, 17 Disintegrants & Superdisintegrants, 17 Coating Systems & Additives, 13 Direct Compression, 13 Lubricants & Glidants, 10 Thickeners and Stabilizers, 9 Controlled & Modified Release, 8 Granulation, 6 Co-Processed Excipients, 5 Film Formers & Plasticizers, 3 Taste Masking, 3 Topical, 3 Parenteral, 2 Rheology Modifiers, 2 Chewable & Orodispersible Aids, 1 API Stability Enhancers, 1 Solubilizers, 1 Emulsifying Agents

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions

2 US Medicaid Prescriptions

MARKET PLACE

1 APIs

1 APIs

PATENTS

63 US Patents, 26 US Exclusivities

DIGITAL CONTENT

11 News

11 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

EU WC

Listed Suppliers

API REF. PRICE (USD / KG)

4,949

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

271.00

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: Bosutinib hydrate, 918639-08-4, Ski-606 monohydrate, Bosutinib.h2o, Bosutinib (hydrate), 844zje6i55

Molecular Formula

C₂₆H₃₁Cl₂N₅O₄

Molecular Weight

548.5 g/mol

InChI Key

BXPOSPOKHGNMEP-UHFFFAOYSA-N

FDA UNII

844ZJE6I55

Bosutinib Monohydrate is the monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.

1 2D Structure

Bosutinib Monohydrate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;hydrate

2.1.2 InChI

InChI=1S/C26H29Cl2N5O3.H2O/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27;/h11-14,16H,4-10H2,1-3H3,(H,30,31);1H2

2.1.3 InChI Key

BXPOSPOKHGNMEP-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC.O

2.2 Other Identifiers

2.2.1 UNII

844ZJE6I55

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. Bosutinib Hydrate

2. 918639-08-4

3. Ski-606 Monohydrate

4. Bosutinib.h2o

5. Bosutinib (hydrate)

6. 844zje6i55

7. Bosutinib Hydrate (jan)

8. 3-quinolinecarbonitrile, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-, Hydrate (1:1)

9. 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;hydrate

10. Bosutinib Hydrate [jan]

11. Bosutinib (as Monohydrate)

12. 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Monohydrate

13. 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile--water (1/1)

14. Bosutinibhydrate

15. Unii-844zje6i55

16. Bosulif (tn)

17. Schembl2887945

18. Chebi:68533

19. Dtxsid20238722

20. Amy16532

21. Bcp17036

22. Hy-10158a

23. Akos027326604

24. Ac-30573

25. Bosutinib Monohydrate [orange Book]

26. Cs-0019907

27. Bosutinib (as Monohydrate) [ema Epar]

28. D09728

29. A900109

30. Q27137001

31. 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl) Propoxy]-3-quinolinecarbonitrile Monohydrate

32. 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile Monohydrate

2.4 Create Date

2007-02-05

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₃₁Cl₂N₅O₄
Molecular Weight	548.5 g/mol
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	9
Exact Mass	547.1753099 g/mol
Monoisotopic Mass	547.1753099 g/mol
Topological Polar Surface Area	83.9 Å²
Heavy Atom Count	37
Formal Charge	0
Complexity	734
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Bosulif
PubMed Health	Bosutinib (By mouth)
Drug Classes	Antineoplastic Agent
Active Ingredient	Bosutinib monohydrate
Dosage Form	Tablet
Route	Oral
Strength	eq 100mg base; eq 500mg base
Market Status	Prescription
Company	Wyeth Pharms

2 of 2
Drug Name	Bosulif
PubMed Health	Bosutinib (By mouth)
Drug Classes	Antineoplastic Agent
Active Ingredient	Bosutinib monohydrate
Dosage Form	Tablet
Route	Oral
Strength	eq 100mg base; eq 500mg base
Market Status	Prescription
Company	Wyeth Pharms

4.2 Drug Indication

Bosulif is indicated for the treatment of adult patients with:

- newlydiagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).

- CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

5 Pharmacology and Biochemistry

5.1 FDA Pharmacological Classification

5.1.1 Pharmacological Classes

Kinase Inhibitor [EPC]; Bcr-Abl Tyrosine Kinase Inhibitors [MoA]